Focus of the Report: This report evaluates the use of tisagenlecleucel (Kymriah) for the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) or r/r diffuse large B-cell lymphoma (DLBCL).
Technology Description: Tisagenlecleucel therapy is a form of chime…